Close Menu

NEW YORK (GenomeWeb) – Interpace Diagnostics announced today that it has received approval to launch its ThyGeNext assay in New York and Pennsylvania, allowing the firm to sell the thyroid cancer detection assay to physicians in the two states.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.